Capnia Inc. (CAPN) 6.06 $CAPN
Capnia on the move
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 12:30PM CDT
CAPN: 6.06 (-0.30)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 11:47AM CDT
BAK: 6.88 (+0.14), MELA: 3.25 (+0.21), ZGNX: 1.31 (+0.01), EOX: 0.90 (-0.11), MRD: 16.30 (-1.24), ULTR: 1.18 (+0.02), BLT: 13.29 (-0.12), RESN: 9.16 (-0.84), GBSN: 2.39 (+0.03), CYTX: 1.32 (+0.12), WRES: 1.00 (-0.05), MTL: 1.03 (-0.51), VRA: 15.51 (+0.26), CTP: 6.91 (-0.34), ENRJ: 1.52 (+0.02), CORT: 4.16 (+0.16), CBMG: 40.20 (+0.64), SPP: 1.70 (-0.30), CAPN: 6.06 (-0.30), SZYM: 2.78 (-0.25)
Capnia reports Q4 results
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 3:40PM CDT
CAPN: 6.06 (-0.30)
Capnia Reports Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Tue Mar 10, 3:05PM CDT
Capnia, Inc. (Nasdaq:CAPN), focused on the development of novel products based on its proprietary technologies for precision metering of gas flow, today announced financial results for the fourth quarter and twelve months ended December 31, 2014.
CAPNU: (), CAPN: 6.06 (-0.30)
Capnia's Exercise Of Series B Warrants Provides Clarity On Share Structure, Increases Valuation
Edward Vranic, CFA - at Seeking Alpha - Fri Mar 06, 6:14AM CST
CAPN: 6.06 (-0.30)
Premarket Gainers / Losers as of 9:20 am
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:24AM CST
CBI: 45.39 (-0.09), SSH: 4.18 (+0.01), CRIS: 2.91 (-0.11), PERI: 3.24 (-0.03), PBR.A: 5.11 (+0.01), RUBI: 17.86 (-0.17), BNFT: 37.36 (-0.90), BIOC: 2.60 (-0.22), AMPE: 7.48 (-0.50), NBG: 1.26 (+0.03), WGBS: 4.69 (-0.26), HPQ: 32.33 (-0.10), WBAI: 11.78 (+0.18), PBR: 5.00 (-0.01), SMSI: 1.18 (-0.05), LC: 18.92 (-0.15), CLRX: 1.08 (+0.01), CHK: 13.78 (-0.02), BSFT: 33.58 (-0.06), SFXE: 4.17 (-0.13), ATRS: 2.67 (+0.02), CHS: 17.99 (+0.07), CAPN: 6.06 (-0.30), SLCA: 28.09 (-1.37)
The Pop Of Capnia's Share Price Will Be Short Lived
Probio Invest - at Seeking Alpha - Wed Feb 25, 12:34AM CST
CAPN: 6.06 (-0.30)
A Recent Healthcare IPO That Could Lead To Big Gains For Investors On Improved Care For Newborns
Edward Vranic, CFA - at Seeking Alpha - Mon Feb 23, 3:06PM CST
GENE: 4.50 (-0.21), BABY: 36.84 (+0.61), CAPN: 6.06 (-0.30)
Investors Are Betting On Big Gains For Capnia
Edward Vranic, CFA - at Seeking Alpha - Fri Feb 20, 8:46AM CST
CAPN: 6.06 (-0.30)
Capnia Announces First U.S. Commercial Sales of CoSense(R)
GlobeNewswire - Tue Feb 17, 6:19AM CST
Capnia, Inc. (Nasdaq:CAPN), focused on the development of novel products based on its proprietary technologies for precision metering of gas flow, today announced the first U.S. commercial sales of the Company's CoSense End-Tidal Carbon Monoxide (ETCO) Monitors and single-use sampling sets to leading academic, research and healthcare institutions. CoSense is a portable, non-invasive device that rapidly and accurately measures carbon monoxide in exhaled breath. The measurement of carbon monoxide is the gold standard for measuring hemolysis, a condition that, if left untreated, may lead to elevated levels of bilirubin in the blood and a range of neurodevelopmental disorders in newborns.
CAPNU: (), CAPN: 6.06 (-0.30)
Capnia Announces Publication of CoSense® Scientific Data in the Journal Blood Cells, Molecules and Diseases
PR Newswire - Wed Jan 28, 6:00AM CST
Capnia, Inc. (NASDAQ: CAPN), focused on the development of novel diagnostics and therapeutics based on its proprietary technologies for precision metering of gas flow, today announced a paper, titled "End-tidal carbon monoxide as an indicator of the hemolytic rate," has been published online in the journal Blood Cells, Molecules and Diseases.
CAPNU: (), CAPN: 6.06 (-0.30)
Capnia Applies for Orphan Drug Designation in the U.S. for the Treatment of Trigeminal Neuralgia
PR Newswire - Thu Jan 08, 6:00AM CST
Capnia, Inc. (NASDAQ: CAPN), focused on the development of novel diagnostics and therapeutics based on its proprietary technologies for precision metering of gas flow, today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Orphan Drug Designation for its nasal, non-inhaled carbon dioxide (nasal CO2) technology for the treatment of trigeminal neuralgia (TN).
CAPNU: (), CAPN: 6.06 (-0.30)
Capnia and Clinvest® Partner to Develop Cluster Headache Therapeutic
PR Newswire - Tue Jan 06, 6:00AM CST
Capnia, Inc. (NASDAQ: CAPN), focused on the development of novel diagnostics and therapeutics based on its proprietary technologies for precision metering of gas flow, and Clinvest®, a research organization dedicated to the advancement of medicine and health management through clinical research, announced the execution of a Memorandum of Understanding (MOU), whereby the parties will collaborate to develop a therapeutic product for the treatment of cluster headache using Capnia's proprietary nasal, non-inhaled carbon dioxide (nasal CO2) technology.
CAPNU: (), CAPN: 6.06 (-0.30)
Capnia to Present at OneMedForum 2015
PR Newswire - Mon Jan 05, 6:00AM CST
Capnia, Inc. (NASDAQ: CAPN), focused on the development of novel diagnostics and therapeutics based on its proprietary technologies for precision metering of gas flow, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at OneMedForum 2015 on Tuesday, January 13th, 2015 at 12:10 PM PT in San Francisco. Dr. Bhatnagar will be providing a corporate presentation, as well as a business update since Capnia completed its initial public offering on November 18, 2014. The presentation can be viewed after January 13, 2015 on the Company's website at http://investors.capnia.com/events-and-presentations.
CAPNU: (), CAPN: 6.06 (-0.30)
Capnia reports Q3 loss
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 3:28PM CST
CAPN: 6.06 (-0.30)
Capnia Reports Third Quarter 2014 Financial Results
PR Newswire - Thu Dec 18, 3:05PM CST
Capnia, Inc. (NASDAQ: CAPN), focused on the development of medical diagnostics based on its proprietary Sensalyze(TM) Technology Platform for precision metering of gas flow, today announced financial results for the third quarter and nine months ended September 30, 2014.
CAPNU: (), CAPN: 6.06 (-0.30)
Capnia on the move
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 12:30PM CDT
CAPN: 6.06 (-0.30)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 11:47AM CDT
BAK: 6.88 (+0.14), MELA: 3.25 (+0.21), ZGNX: 1.31 (+0.01), EOX: 0.90 (-0.11), MRD: 16.30 (-1.24), ULTR: 1.18 (+0.02), BLT: 13.29 (-0.12), RESN: 9.16 (-0.84), GBSN: 2.39 (+0.03), CYTX: 1.32 (+0.12), WRES: 1.00 (-0.05), MTL: 1.03 (-0.51), VRA: 15.51 (+0.26), CTP: 6.91 (-0.34), ENRJ: 1.52 (+0.02), CORT: 4.16 (+0.16), CBMG: 40.20 (+0.64), SPP: 1.70 (-0.30), CAPN: 6.06 (-0.30), SZYM: 2.78 (-0.25)
Capnia reports Q4 results
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 3:40PM CDT
CAPN: 6.06 (-0.30)
Capnia Reports Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Tue Mar 10, 3:05PM CDT
Capnia, Inc. (Nasdaq:CAPN), focused on the development of novel products based on its proprietary technologies for precision metering of gas flow, today announced financial results for the fourth quarter and twelve months ended December 31, 2014.
CAPNU: (), CAPN: 6.06 (-0.30)
Capnia's Exercise Of Series B Warrants Provides Clarity On Share Structure, Increases Valuation
Edward Vranic, CFA - at Seeking Alpha - Fri Mar 06, 6:14AM CST
CAPN: 6.06 (-0.30)
Premarket Gainers / Losers as of 9:20 am
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:24AM CST
CBI: 45.39 (-0.09), SSH: 4.18 (+0.01), CRIS: 2.91 (-0.11), PERI: 3.24 (-0.03), PBR.A: 5.11 (+0.01), RUBI: 17.86 (-0.17), BNFT: 37.36 (-0.90), BIOC: 2.60 (-0.22), AMPE: 7.48 (-0.50), NBG: 1.26 (+0.03), WGBS: 4.69 (-0.26), HPQ: 32.33 (-0.10), WBAI: 11.78 (+0.18), PBR: 5.00 (-0.01), SMSI: 1.18 (-0.05), LC: 18.92 (-0.15), CLRX: 1.08 (+0.01), CHK: 13.78 (-0.02), BSFT: 33.58 (-0.06), SFXE: 4.17 (-0.13), ATRS: 2.67 (+0.02), CHS: 17.99 (+0.07), CAPN: 6.06 (-0.30), SLCA: 28.09 (-1.37)
The Pop Of Capnia's Share Price Will Be Short Lived
Probio Invest - at Seeking Alpha - Wed Feb 25, 12:34AM CST
CAPN: 6.06 (-0.30)
A Recent Healthcare IPO That Could Lead To Big Gains For Investors On Improved Care For Newborns
Edward Vranic, CFA - at Seeking Alpha - Mon Feb 23, 3:06PM CST
GENE: 4.50 (-0.21), BABY: 36.84 (+0.61), CAPN: 6.06 (-0.30)
Investors Are Betting On Big Gains For Capnia
Edward Vranic, CFA - at Seeking Alpha - Fri Feb 20, 8:46AM CST
CAPN: 6.06 (-0.30)
Capnia Announces First U.S. Commercial Sales of CoSense(R)
GlobeNewswire - Tue Feb 17, 6:19AM CST
Capnia, Inc. (Nasdaq:CAPN), focused on the development of novel products based on its proprietary technologies for precision metering of gas flow, today announced the first U.S. commercial sales of the Company's CoSense End-Tidal Carbon Monoxide (ETCO) Monitors and single-use sampling sets to leading academic, research and healthcare institutions. CoSense is a portable, non-invasive device that rapidly and accurately measures carbon monoxide in exhaled breath. The measurement of carbon monoxide is the gold standard for measuring hemolysis, a condition that, if left untreated, may lead to elevated levels of bilirubin in the blood and a range of neurodevelopmental disorders in newborns.
CAPNU: (), CAPN: 6.06 (-0.30)
Capnia Announces Publication of CoSense® Scientific Data in the Journal Blood Cells, Molecules and Diseases
PR Newswire - Wed Jan 28, 6:00AM CST
Capnia, Inc. (NASDAQ: CAPN), focused on the development of novel diagnostics and therapeutics based on its proprietary technologies for precision metering of gas flow, today announced a paper, titled "End-tidal carbon monoxide as an indicator of the hemolytic rate," has been published online in the journal Blood Cells, Molecules and Diseases.
CAPNU: (), CAPN: 6.06 (-0.30)
Capnia Applies for Orphan Drug Designation in the U.S. for the Treatment of Trigeminal Neuralgia
PR Newswire - Thu Jan 08, 6:00AM CST
Capnia, Inc. (NASDAQ: CAPN), focused on the development of novel diagnostics and therapeutics based on its proprietary technologies for precision metering of gas flow, today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Orphan Drug Designation for its nasal, non-inhaled carbon dioxide (nasal CO2) technology for the treatment of trigeminal neuralgia (TN).
CAPNU: (), CAPN: 6.06 (-0.30)
Capnia and Clinvest® Partner to Develop Cluster Headache Therapeutic
PR Newswire - Tue Jan 06, 6:00AM CST
Capnia, Inc. (NASDAQ: CAPN), focused on the development of novel diagnostics and therapeutics based on its proprietary technologies for precision metering of gas flow, and Clinvest®, a research organization dedicated to the advancement of medicine and health management through clinical research, announced the execution of a Memorandum of Understanding (MOU), whereby the parties will collaborate to develop a therapeutic product for the treatment of cluster headache using Capnia's proprietary nasal, non-inhaled carbon dioxide (nasal CO2) technology.
CAPNU: (), CAPN: 6.06 (-0.30)
Capnia to Present at OneMedForum 2015
PR Newswire - Mon Jan 05, 6:00AM CST
Capnia, Inc. (NASDAQ: CAPN), focused on the development of novel diagnostics and therapeutics based on its proprietary technologies for precision metering of gas flow, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at OneMedForum 2015 on Tuesday, January 13th, 2015 at 12:10 PM PT in San Francisco. Dr. Bhatnagar will be providing a corporate presentation, as well as a business update since Capnia completed its initial public offering on November 18, 2014. The presentation can be viewed after January 13, 2015 on the Company's website at http://investors.capnia.com/events-and-presentations.
CAPNU: (), CAPN: 6.06 (-0.30)
Capnia reports Q3 loss
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 3:28PM CST
CAPN: 6.06 (-0.30)
Capnia Reports Third Quarter 2014 Financial Results
PR Newswire - Thu Dec 18, 3:05PM CST
Capnia, Inc. (NASDAQ: CAPN), focused on the development of medical diagnostics based on its proprietary Sensalyze(TM) Technology Platform for precision metering of gas flow, today announced financial results for the third quarter and nine months ended September 30, 2014.
CAPNU: (), CAPN: 6.06 (-0.30)
